Compliance Rate
Compliance Rate
50.0%
Compliant submissions
1
Incompliant submissions
1
Total trials
2
My Organizations' Clinical Trials
Showing 2425 of 3499 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/12/08
End: 10/18/19
Due: 10/18/20
Phase: N/A
Priority: Normal
Start: 08/31/99
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/30/00
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/31/00
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/09/19
End: 12/11/25
Due: 12/11/26
Phase: N/A
Priority: Normal
Start: 01/29/19
End: 08/30/25
Due: 08/30/26
Phase: N/A
Priority: Normal
Start: 10/01/15
End: 07/10/20
Due: 07/10/21
Phase: N/A
Priority: Normal
Start: 08/24/09
End: 01/31/18
Due: 01/31/19
Phase: N/A
Priority: Normal
Start: 08/31/00
End: 02/28/09
Due: 02/28/10
Phase: N/A
Priority: Normal
Start: 09/09/21
End: 07/05/23
Due: 07/05/24
Phase: N/A
Priority: Normal
Start: 12/31/07
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 03/25/03
End: 02/13/20
Due: 02/13/21
Phase: N/A
Priority: Normal
Start: 09/10/08
End: 04/19/11
Due: 04/19/12
Phase: N/A
Priority: Normal
Start: 11/30/00
End: 07/31/02
Due: 07/31/03
Phase: N/A
Priority: Normal
Start: 05/31/03
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/22/13
End: 02/28/20
Due: 02/28/21
Phase: N/A
Priority: Normal
Start: 08/26/09
End: 02/26/20
Due: 02/26/21
Phase: N/A
Priority: Normal
Start: 10/11/17
End: 03/12/21
Due: 03/12/22
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Phase: N/A
Priority: Normal
Start: 10/31/08
End: 02/14/18
Due: 02/14/19
Phase: N/A
Priority: Normal
Start: 05/10/10
End: 11/18/11
Due: 11/18/12
Phase: N/A
Priority: Normal
Start: 06/30/04
End: 01/31/09
Due: 01/31/10
Phase: N/A
Priority: Normal
Start: 10/31/10
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/00
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/19/05
End: 04/18/18
Due: 04/18/19
Phase: N/A
Priority: Normal
Start: 09/24/01
End: 10/07/20
Due: 10/07/21